Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4140-4152

  Habashita, Hiromu ^a   Kokubo, Masaya ^a   Hamano, Shin Ichi ^a   Hamanaka, Nobuyuki ^a   Toda, Masaaki ^a   Shibayama, Shiro ^a   Tada, Hideaki ^a   Sagawa, Kenji ^a   Fukushima, Daikichi ^a   Maeda, Kenji ^b   Mitsuya, Hiroaki ^b,c  

^a ONO PHARMACEUTICAL CO   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BUTYL 3 (2 METHYLPROPYL) 9 (4 PHENOXYPHENYLMETHYL) 1,4,9 TRIAZASPIRO[5.5]UNDECA 2,5 DIONE; 1 BUTYL 3 (2 METHYLPROPYL) 9 (6 PHENYLHEXYL) 1,4,9 TRIAZASPIRO[5.5]UNDECA 2,5 DIONE; 1,4,9 TRIAZASPIRO[5.5]UNDECA 2,5 DIONE; 9 (1,4 BENZODIOXAN 6 YL) 1 BUTYL 3 CYCLOHEXYL 1,4,9 TRIAZASPIRO[5.5]UNDECA 2,5 DIONE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; ISONITRILE DERIVATIVE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; COMBINATORIAL LIBRARY; CYTOTOXICITY; DRUG DESIGN; DRUG RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; CALCIUM; CHO CELLS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRICETINAE; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV-1; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MODELS, MOLECULAR; MOLECULAR WEIGHT; PIPERAZINES; RECEPTORS, CCR5; SPIRO COMPOUNDS; VIRUS REPLICATION;

EID: 33745807624     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060051s     Document Type: Article

References (44)

1. Schwarz, M. K.; Wells, T. N. C. New therapeutics that modulate chemokine networks. Nat. Rev. 2002, 1, 347-358.
2. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272, 872-877.
3. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381, 661-666.
4. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381, 667-673.
5. Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. A. CC CKR5: a RANTES, MIP-1α, MIP-1α receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272, 1955-1958.
6. Holmes, W. E.; Lee, J.; Kuang, W. J.; Rice, G. C.; Wood, W. I. Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253, 1278-1280.
7. Murphy, P. M.; Tiffany, H. L. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991, 253, 1280-1283.
8. Muller, G. Medicinal chemistry of target family directed masterkeys. Drug Discovery Today 2003, 8, 681-691.
9. Horuk, R. Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 2003, 29, 369-375.
10. For examples see the following: (a) White, J. R.; Lee, J. M.; Young, P. R.; Hertzberg, R. P.; Jurewicz, A. J.; Chaikin, M. A.; Widdowson, K.; Foley, J. J.; Martin, L. D.; Griswold, D. E.; Sarau, H. M. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 1998, 273, 10095-10098.
11. (b) Hesselgesser, J.; Ng, H. P.; Liang, M.; Zheng, W.; May, K.; Bauman, J. G.; Monahan, S.; Islam, I.; Wei, G. P.; Ghannam, A.; Taub, D. D.; Rosser, M.; Snider, R. M.; Morrissey, M. M.; Perez, H. D.; Horuk, R. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. 1998, 273, 15687-15692.
12. (c) Howard, O. M.; Korte, T.; Tarasova, N. I.; Grimm, M.; Turpin, J. A.; Rice, W. G.; Michejda, C. J.; Blumenthal, R.; Oppenheim, J. J. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J. Leukocyte Biol. 1998, 64, 6-13.
13. Dolle, R. E. Comprehensive survey of combinatorial library synthesis: 2004. J. Comb. Chem. 2005, 7, 739-798.
14. Thompson, L. A.; Ellman, J. A. Synthesis and applications of small molecule libraries. Chem. Rev. 1996, 96, 555-600.
15. Pachett, A. A.; Nargund, R. P. Privileged structures - an update. In Annual Reports in Medicinal Chemistry; Doherty, A. M., Ed.; Academic Press: San Diego, CA, 2000; Vol. 35, pp 289-298.
16. Fischer, P. M. Diketopiperazines in peptide and combinatorial chemistry. J. Pept. Sci. 2003, 9, 9-35.
17. Vartanyan, S. A.; Tosunyan, A. O.; Madakyan, V. N. Synthesis and reaction of 1,2,5-trimethyl-4-aminopiperidine-4-carboxylic acid. Arm. Khim. Zh. 1972, 25, 163-167.
18. For preparations of diketopiperazine via Ugi MCR see the following: (a) Keating, T. A.; Armstrong, R. W. A remarkable two-step synthesis of diverse 1,4-benzodiazepine-2,5-diones using the Ugi four-component condensation. J. Org. Chem. 1996, 61, 8935.
19. (b) Hulme, C.; Cherrier, M.-P. Novel applications of ethyl glyoxalate with the Ugi MCR. Tetrahedron Lett. 1999, 40, 5296-5299.
20. (c) Hulme, C.; Ma, L.; Kumar, V. N.; Krolikowski, P. H.; Allen, A. C.; Labaudiniere, R. Novel applications of resin bound α-amino acids for the synthesis of benzodiazepines (via Wang resin) and ketopiperazines (via hydroxymethyl resin). Tetrahedron Lett 2000, 41, 1509-1514.
21. (d) Golebiowski, A.; Jozwik, J.; Klopfenstein, S. R.; Colson, A.-O.; Grieb, A. L.; Russell, A. F.; Rastogi, V. L.; Diven, C. F.; Portlock, D. E.; Chen, J. J. Solid-supported synthesis of putative peptide-turn mimetics via Ugi reaction for diketopiperazine formation. J. Comb. Chem. 2002, 4, 584-590.
22. (e) Kennedy, A. L.; Fryer, A. M.; Josey, J. A. A new resin-bound universal isonitrile for the Ugi 4CC reaction: preparation and applications to the synthesis of 2,5-diketopiperazines and 1,4-benzodiazepine-2,5-diones. Org. Lett. 2002, 4, 1167-1170.
23. Domling, A.; Ugi, I. Multicomponent reactions with isocyanides. Angew. Chem., Int. Ed. 2000, 39, 3168-3210.
24. Chen, J. J.; Golebiowski, A.; Klopfenstein, S. R.; West, L. The universal Rink-isonitrile resin: applications in Ugi reactions. Tetrahedron Lett. 2002, 43, 4083-4085.
25. Hulme, C.; Ma, L.; Cheerier, M.-P.; Romano, J. J.; Morton, G.; Duquenne, C.; Salvino, J.; Labaudiniere, R. Novel applications of convertible isonitriles for the synthesis of mono and bicyclic γ-lactams via a UDC strategy. Tetrahedron Lett. 2000, 41, 1883-1887.
26. Zhang, A. J.; Russell, D. H.; Zhu, J.; Burgess, K. A method for removal of N-BOC protecting groups from substrates on TFA-sensitive resins. Tetrahedron Lett. 1998, 39, 7439-7442.
27. After the completion of this work, we reinvestigated whether epimerization occurred with optically pure amino acids during synthesis, as shown in Scheme 1. In some cases, epimerization could be observed. As a result of an investigation to avoid this epimerization, we found that the removal of acetic acid in the diketopiperazine formation step completely prevented epimerization. For details, see the Supporting Information.
28. In the synthesis of compound 1e, 1,9-bis(5-phenylpentyl)-3-(2- methylpropyl)-1,4,9-triazaspiro[5.5]undeca-2,5-dione was obtained in 45% yield. This result indicated that 1-(5-phenypentyl)-4-piperidone might decompose during the reaction to produce 5-phenylpentylamine. For the decomposition of 4-piperidone, see the following: (a) Shimano, M.; Meyers, A. I. Asymmetric Michael-type additions of lithium amides to aromatic systems leading to novel β-amino acids. J. Am. Chem. Soc. 1994, 116, 6437-6438.
29. (b) Shimano, M.; Meyers, A. I. Asymmetric diastereoselective conjugate additions of lithium amides to chiral naphthyloxazolines leading to novel β-amino acids. J. Org. Chem. 1995, 60, 7445-7455.
30. Fernandez-Forner, D.; Casals, G.; Navarro, E.; Ryder, H.; Albericio, F. Solid-phase synthesis of 4-aminopiperidine analogues using the Alloc protecting group: an investigation of Alloc removal from secondary amines. Tetrahedron Lett. 2001, 42, 4471-4474.
31. Dangles, O.; Guibe, F.; Balavoine, G.; Lavielle, S.; Marquet, A. Selective cleavage of the allyl and (allyloxy)carbonyl groups through palladium-catalyzed hydrostannolysis with tributyltin hydride. Application to the selective protection-deprotection of amino acid derivatives and in peptide synthesis. J. Org. Chem. 1987, 52, 4984-4993.
32. Gordon, D. W.; Steele, J. Reductive alkylation on a solid phase: Synthesis of a piperazinedione combinatorial library. Bioorg. Med. Chem. Lett. 1995, 5, 47-50.
33. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J. Org. Chem. 1996, 61, 3849-3862.
34. Siegel, M. G.; Hahn, P. J.; Dressman, B. A.; Fritz, J. E.; Grunwell, J. R.; Kaldor, S. W. Rapid purification of small molecule libraries by ion exchange chromatography. Tetrahedron Lett. 1997, 38, 3357-3360.
35. In the initial screening, the compound synthesized from 1-propylamine, 1-(2-phenylethyl)-4-piperidone, and Boc-Lys(Z)-OH was identified as a selective micromolar hCCR2 antagonist. The details will be reported in due course.
36. 50 values represent the average of two or more determinations, and the standard deviations were no greater than 30% from the mean.
37. Barber, C. G. CCR5 antagonists for the treatment of HIV. Curr. Opin. Invest. Drugs 2004, 5, 851-861.
38. Hall, I. P.; Wheatley, A.; Christie, G.; McDougall, C.; Hubbard, R.; Helms, P. J. Association of CCR5 Δ32 with reduced risk of asthma. Lancet 1999, 354, 1264-1265.
39. Vierboom, M. P.; Zavodny, P. J.; Chou, C. C.; Tagat, J. R.; Pugliese-Sivo, C.; Strizki, J.; Steensma, R. W.; McCombie, S. W.; Celebi-Paul, L.; Remarque, E.; Jonker, M.; Narula, S. K.; Hart, B. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum. 2005, 52, 627-636.
40. Fischereder, M.; Luckow, B.; Hocher, B.; Wuthrich, R. P.; Rothenpieler, U.; Schneeberger, H.; Panzer, U.; Stahl, R. A.; Hauser, I. A.; Budde, K.; Neumayer, H.; Kramer, B. K.; Land, W.; Schlondorff, D. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001, 357, 1758-1761.
41. Thoma, G.; Nuninger, F.; Schaefer, M.; Akyel, K. G.; Albert, R. Beerli, C.; Bruns, C.; Francotte, E.; Luyten, M.; MacKenzie, D. Oberer, L.; Streiff, M. B.; Wagner, T.; Walter, H.; Weckbecker, G. Zerwes, H. G. Orally bioavailable competitive CCR5 antagonists. J. Med. Chem. 2004, 47, 1939-1955.
42. Haque, T. S.; Skillman, A. G.; Lee, C. E.; Habashita, H.; Gluzman, I. Y.; Ewing, T. J.; Goldberg, D. E.; Kuntz, I. D.; Ellman, J. A. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J. Med. Chem. 1999, 42, 1428-1440.
43. Interestingly, the compound with building block R1-CR (3,5-dimethyl-1-phenylpyrazol-3-ylmethyl group) was identified as a potent functional agonist in the calcium assay. The details of the biological characterization and preliminary SAR investigation will be reported in due course.
44. Maeda, K.; Yoshimura, K.; Shibayama, S.; Habashita, H.; Tada, H.; Sagawa, K.; Miyakawa, T.; Aoki, M.; Fukushima, D.; Mitsuya, H. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol. Chem. 2001, 276, 35194-35200.